{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-063019","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.584231+00:00","generated_at":"2026-06-08T05:21:41.132928+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Revelation Biosciences reports Q3 2023 net loss of $2.6M; cash $14.0M","bullets":["Net loss $2.6M ($0.42/share) vs loss $1.2M ($1.91/share) in Q3 2022; nine-month net income $2.1M on $8.3M warrant gain.","Cash and equivalents $14.0M at Sep 30, 2023, up from $5.3M at Dec 31, 2022; runway through Sep 2024.","Operating cash burn for nine months 2023 was $5.3M vs $10.3M in 2022, driven by lower clinical study expenses.","Gemini preclinical data showed significant mobilization of neutrophils, monocytes, lymphocytes and upregulation of IL-10, NGAL, IL-6.","Phase 1 clinical study of Gemini expected to begin near end of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-063019","json":"https://secwatch.observer/filing/0000950170-23-063019.json","markdown":"https://secwatch.observer/filing/0000950170-23-063019.md","text":"https://secwatch.observer/filing/0000950170-23-063019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023063019/0000950170-23-063019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023063019/revb-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:21:41.132928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95f92f720863cf2d342816b022c82ad71b9ae435","claim":"REVELATION BIOSCIENCES, INC. reported three and nine months ended September 30, 2023 results: net income $2.6 million, or $0.42 basic and diluted net loss per share.","evidence_excerpt":"Revelation’s net loss for the three months ended September 30, 2023 was $2.6 million, or $0.42 basic and diluted net loss per share, compared to a net loss of $1.2 million, or $1.91 basic and diluted net loss per share for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023063019/0000950170-23-063019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Net income","value":"$2.6 million, or $0.42 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}